Work

Ixekizumab: an alternative for HIV-positive psoriasis patients

Year: 2024

Type: article

Abstract: Psoriasis is a recurrent and protracted inflammatory disease. Generalized erythema, plaques, and silvery scales on the surface mainly characterize its skin lesions. Biologics bring new hope to psoriasis patients. However, HIV infection is a major concern before receiving biologics. Here, we present a case of the efficacy and safety of Ixekizumab, an interleukin 17 inhibitor, in the treatment of psoriasis patients living with HIV (PPLHIV).

Source: AIDS Research and Therapy

DOI: 10.1186/s12981-024-00675-8

Authors: Fanghua Liu, Zhou Liu, Rongming Yang, Dandan Huang, Yongzhi Han

Institutions: Ganzhou People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,890